title: Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia.
abstract: This report by an international consensus panel updates current recommendations for defining clinical response in Waldenstrom's macroglobulinemia (WM). The previously published response criteria incorporated parameters for monoclonal protein reduction and/or improvement of marrow and nodal involvement, and included definitions of complete and partial remissions. The criteria have been updated to include minor response and stable disease categories. In addition, the criteria now recognize that delayed responses after treatment with nucleoside analogues and biologic agents and the time point for assessing response in patients with WM should be considered so as to not miss or miscategorize a response. The new criteria should therefore help in better delineating responses to therapy in patients with WM, particularly with the wide use of nucleoside analogues and biologically based agents for this disease.
authors.affiliation: Karolinska University Hospital, Stockholm, Sweden.
authors.forename: Eva
authors.initials: E
authors.lastname: Kimby
authors.forename: Steven P
authors.initials: SP
authors.lastname: Treon
authors.forename: Athanasios
authors.initials: A
authors.lastname: Anagnostopoulos
authors.forename: Meletios
authors.initials: M
authors.lastname: Dimopoulos
authors.forename: Ramon
authors.initials: R
authors.lastname: Garcia-Sanz
authors.forename: Morie A
authors.initials: MA
authors.lastname: Gertz
authors.forename: Stephen
authors.initials: S
authors.lastname: Johnson
authors.forename: Veronique
authors.initials: V
authors.lastname: LeBlond
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Fermand
authors.forename: David G
authors.initials: DG
authors.lastname: Maloney
authors.forename: Giampaolo
authors.initials: G
authors.lastname: Merlini
authors.forename: Pierre
authors.initials: P
authors.lastname: Morel
authors.forename: Enrica
authors.initials: E
authors.lastname: Morra
authors.forename: Gwen
authors.initials: G
authors.lastname: Nichols
authors.forename: Enrique M
authors.initials: EM
authors.lastname: Ocio
authors.forename: Roger
authors.initials: R
authors.lastname: Owen
authors.forename: Marvin
authors.initials: M
authors.lastname: Stone
authors.forename: Joan
authors.initials: J
authors.lastname: Bladé
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001536:Bence Jones Protein / Q000032:analysis; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000379:methods*; D003131:Combined Modality Therapy; D018450:Disease Progression; D005260:Female; D006801:Humans; D007075:Immunoglobulin M / Q000032:analysis; D007391:International Cooperation; D008297:Male; D011379:Prognosis; D018570:Risk Assessment; D055502:Secondary Prevention; D012720:Severity of Illness Index; D016019:Survival Analysis; D017211:Treatment Failure; D016896:Treatment Outcome; D014481:United States; D008258:Waldenstrom Macroglobulinemia / Q000175:diagnosis* / Q000401:mortality* / Q000628:therapy
chemical_list: D007075:Immunoglobulin M; D001536:Bence Jones Protein